New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:12 EDTRCPTReceptos says Phase 2 study of RPC1063 met primary efficacy endpoint
Receptos announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.
News For RCPT From The Last 14 Days
Check below for free stories on RCPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
12:02 EDTRCPTReceptos price target raised to $80 from $63 at Wedbush
Subscribe for More Information
10:59 EDTRCPTReceptos price target raised to $77 from $60 at Leerink
Subscribe for More Information
07:48 EDTRCPTReceptos price target raised to $75 from $58 at Credit Suisse
Credit Suisse raised Receptos' price target to $75 citing increased clarity on RPC1063's potential differentiated profile following presentation of further RADIANCE Ph II data. Share are Outperform rated.
September 10, 2014
16:19 EDTRCPTOn The Fly: Closing Wrap
Subscribe for More Information
15:05 EDTRCPTReceptos surges after abstracts for RADIANCE trial posted
Shares of drugmaker Receptos (RCPT) are sharply higher after an abstract for the company's Phase 2 portion of its RADIANCE trial of RPC1063 in Relapsing Multiple Sclerosis, or RMS, were posted to the site of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS. WHAT'S NEW: This morning, Receptos announced that data from the Phase 2 portion of RADIANCE, the company's Phase 2/3 trial of RPC1063 in RMS, will be reviewed in a late breaker oral podium presentation at MS Boston on September 13. MS Boston is a joint meeting of ECTRIMS and ACTRIMS, which is the U.S. and Canadian counterpart to ECTRIMS. ANALYST REACTION: Analysts at BMO Capital said the RADIANCE data confirm differentiation of the drug. The firm has an Outperform rating and $72 price target on the stock. Meanwhile, Leerink said that the full RADIANCE data shows a 53% annualized relapse reduction and supports a "highly differentiated safety profile" for the drug. Leerink has an Outperform rating and $60 price target on shares of Receptos. PRICE ACTION: In late afternoon trading, shares of Receptos were up $11.29, or 24%, to $58.34.
12:50 EDTRCPTReceptos to host conference call
Subscribe for More Information
September 8, 2014
09:27 EDTRCPTLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use